Catherine Broome, MD, Georgetown University Hospital, Washington, DC, comments on the unmet needs in treating and managing cold agglutinin disease (CAD). Although inhibition of the classical complement pathway has addressed the hemolysis associated with the disease, targeting the complement cascade does not alter the level of autoimmune IgM antibody, which is responsible for the acrocyanosis observed in patients. Dr Broome also highlights a need to investigate and better understand the systemic impacts of this disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
